Wall Street Zen Upgrades Zhengye Biotechnology (NASDAQ:ZYBT) to Hold

Key Points

• Zhengye Biotechnology was upgraded to a "hold" rating by Wall Street Zen in a recent research note, indicating a change in market sentiment towards the stock.
• The stock opened at $5.30, with a 52-week range between $3.50 and $14.30, showcasing notable volatility in its performance.
• Zhengye Biotechnology specializes in veterinary vaccines, primarily focusing on livestock vaccine production and sales, based in Jilin, China.

Zhengye Biotechnology (NASDAQ:ZYBT - Get Free Report) was upgraded by analysts at Wall Street Zen to a "hold" rating in a report released on Saturday.

Zhengye Biotechnology Stock Performance

Shares of ZYBT stock traded down $0.01 on Friday, reaching $5.75. 3,946 shares of the stock were exchanged, compared to its average volume of 323,300. The company has a current ratio of 1.31, a quick ratio of 0.88 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $6.57 and a two-hundred day moving average of $6.36. Zhengye Biotechnology has a 1-year low of $3.50 and a 1-year high of $14.30.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.